Review

The KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults and Children: Part 1. Definition, Methodology and First-line Management

Woo-Jung Song,1 Mira Choi,22 Dong Hun Lee,1 Jae-Woo Kwon,4 Gun-Woo Kim,8 Myung Hwa Kim,6 Mi-Ae Kim,7 Min-Hye Kim,8 Byung-Keun Kim,9 Sujeong Kim,12 Jung Soo Kim,13 Jung Eun Kim,12 Ju-Young Kim,15 Joo-Hee Kim,14 Hyun Jung Kim,13 Hye One Kim,16 Hyo-Bin Kim,17 Joo Young Roh,18 Kyung Hee Park,19 Kui Young Park,20 Han-Ki Park,21 Hyunsun Park,22 Jung Min Bae,23 Ji Yeon Byun,24 Dae Jin Song,25 Young Min Ahn,26 Seung Eun Lee,27 Young Bok Lee,28 Joong Sun Lee,29 Ji Hyun Lee,30 Kyung-Hwan Lim,31 Young-Min Ye,32 Yoon-Seok Chang,33 You Hoon Jeon,34 Jiyeun Jeon,35 Mi-h-Sook Jue,36 Sun Hee Choi,37 Jeong-Hee Choi,38,39 Gyu-Young Hur,40 Young Min Park,41 Dae Hyun Lim,42† Sang Woong Youn,43†

1Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2Department of Dermatology, Inje University Ilsan Paik Hospital, Ilsan, Korea
3Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea.
4Department of Internal Medicine, Inha University Hospital, 27 Inhang-ro, Jung-gu, Incheon 22332, Korea. Tel: +82-32-890-3658 Fax: +82-32-890-2844 E-mail: dhnlim@naver.com

Sang Woong Youn, MD, PhD
Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea.

†These authors contributed equally to the article.

Copyright © 2020 The Korean Academy of Asthma, Allergy and Clinical Immunology - The Korean Academy of Pediatric Allergy and Respiratory Disease

This is an Open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID IDs
Woo-Jung Song https://orcid.org/0000-0002-4630-9922

https://e-aair.org
ABSTRACT

Chronic spontaneous urticaria (CSU) is defined as the occurrence of spontaneous wheals, angioedema, or both for >6 weeks in the absence of specific causes. It is a common condition associated with substantial disease burden both for affected individuals and societies in many countries, including Korea. CSU frequently persists for several years and requires high-intensity treatment; therefore, patients experience deteriorations in quality of life and medication-associated complications. During the last decade, there have been major advances in the pharmacological treatment of CSU and there is an outstanding need for evidence-based guidelines that reflect clinical practice in Korea. The guidelines reported here represent a joint initiative of the Korean Academy of Asthma, Allergy and Clinical Immunology and the Korean Dermatological Association, and aim to provide evidence-based guidance for the management of CSU in Korean adults and children. In Part 1, disease definition, guideline scope and development methodology as well as evidence-based recommendations on the use of antihistamines and corticosteroids are summarized.

Keywords: Urticaria; guideline; disease management; therapeutics

INTRODUCTION

Urticaria is a common disease characterized by the sudden, unpredictable appearance of wheals, angioedema, or both. There are several subtypes of urticaria defined according to duration, triggers, and associated symptoms and signs. Chronic spontaneous urticaria (CSU) is a major disabling condition that is prevalent in the community and frequently

https://e-aair.org
Korean Guideline for Chronic Spontaneous Urticaria

Definition

Chronic urticaria (CU) is defined as the occurrence of wheals, angioedema, or both for >6 weeks in both adults and children. Chronic urticaria can be divided into CSU and chronic inducible urticaria depending on specific eliciting factors. This guideline focuses on the treatment of CSU.

Epidemiology of CSU in Korea

Approximately 10%–20% of people experience urticaria at some stage in their lives. The global prevalence of CSU is reported to range between 0.02% and 5.0%. In the studies of Korean populations, the prevalence was seen to be 0.16%–2.3%, and it tends to increase each year. The 10-year cumulative incidence rate of urticaria was calculated as 4.9% and that of chronic urticaria among patients with new-onset urticaria was 7.8% in the National Health Insurance Service-National Sample Cohort (NHIS-NSC) data in Korea. In a recent analysis of the Korean Health Insurance Review and Assessment Service (HIRA) database, the median duration of CU was 591 days, and 61.9% of patients had urticaria symptoms that lasted for at least 1 year. In adults with CSU, the remission rate (defined as no hospital visit with a diagnosis of urticaria for at least 1 year) was 21.5% at 1 year, but it was only 44.6% even after 5 years of follow-up. In Korean children with CU, the mean duration to remission was 10.2 months and the remission rate at 24 months was 71.2%.

Risk factors for CSU are largely unknown. In Korean nationwide population-based retrospective cohort studies using the Korean NHIS-NSC, CSU was positively associated with autoimmune thyroid diseases or obesity. In a urban regional population study in Korea, the risk of chronic continuous urticaria was associated with living in a new residence and belonging to a family with high income. Although CSU is not a fatal condition, it restricts and disrupts many facets of patients’ lives. Individuals commonly experience a serious deterioration in quality of life (QoL) due to severe itching, unpredictable occurrence and aggravation of symptoms, anxiety, fatigue, sleep disturbances, cosmetic problems, and the side effects of medication. According to a Korean multicenter study, urticarial activity, dermographism, and emotional stress were strongly associated with QoL impairment. It is commonly elicited by physical factors such as pressure or cold. Psychiatric morbidity is also common in patients with CSU, such as obsessive-compulsive disorder or depression. Due to the significant impact on daily life and activity, the socioeconomic burden of urticaria is also estimated to be substantial, although there has been no direct estimation of the socioeconomic burden of CSU in Korea to date. In other countries, CSU has been associated with a significant reduction in work productivity and increased direct economic loss.

Unmet patient needs in Korea

In our recent questionnaire-based survey of 100 Korean patients with CSU (unpublished data), treatment and diagnosis were the main reasons for medical consultations (93% and...
53%, respectively). Major unmet clinical needs were seen to be a lack of previous treatment efficacy (61%), medical costs (21%), and medication side effects (16%). Patients reported that the following outcomes are important in treatment decision-making: better control of itching (76%), better control of wheals (62%), improvement of QoL (48%), fewer side effects (32%), and lower medical costs (29%).

**Scope of the guidelines**

These guidelines aim to provide evidence-based guidance for the management of CSU in Korean adults and children. The target audience is specialists (allergists and dermatologists) and primary care doctors who manage patients with CSU. Pharmacological and non-pharmacological treatment options are covered, while the diagnostic approach of CU, or treatment of other types of urticaria (acute urticaria or chronic inducible urticaria) is beyond the scope of the present guidelines.

**How to use the guidelines**

The present guidelines aim to provide the basis for rational, informed decision-making for patients, clinicians, and other healthcare professionals. The recommendations should not be viewed as dictates but rather as guidance for typical patients. They are not intended to address unique individual conditions.

**METHODS**

The guideline development committee consisted of clinicians from a range of specialties (allergy, dermatology, pediatrics, and family medicine) and clinical settings (referral hospitals and primary clinics). A methodology specialist (H.J.K.) coordinated and guided the committee members throughout the process of guideline development, including literature search, systematic review, evidence synthesis, and generation of recommendations. Methodological robustness was ensured according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Committee members participated in discussions and arrived at a consensus to formulate key clinical questions to be addressed in the guidelines. They also participated in literature searches, data extraction, evidence synthesis, and formulating recommendations. All members were required to disclose any potential conflicts of interest. The population, intervention, comparison, and outcomes (PICO) format was used to construct the questions. Treatment efficacy (control of urticarial activity and improvement of QoL) and safety (drug side effects) were considered as important outcomes in decision-making.

**Literature search**

PubMed MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Scopus, Web of Science, and KoreaMed databases were searched for relevant articles for each PICO question from inception until July 2017. Manual searches were performed for cross-referenced articles. Also, unpublished randomized controlled trials (RCTs) were retrieved from the ClinicalTrials.gov database. There were no language restrictions.

**Study selection**

Study eligibility was assessed using predefined criteria for each PICO question. Common eligibility criteria for inclusion were: 1) a population with CSU, 2) intervention (or investigation) and/or comparison relevant to each PICO question, and 3) outcomes related to
urticaria. RCTs were considered as the primary source of evidence. However, where no RCTs were available, non-randomized trials were also considered. The eligibility of the retrieved studies was determined by at least 2 independent reviewers per PICO question, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Briefly, the titles and abstracts of the retrieved studies were screened, and the full text was reviewed for potentially relevant papers. Reasons for exclusion were specified. Disagreements among reviewers were resolved by discussion and consensus within the committee.

Assessment of the risk of bias
The risk of bias was assessed using the Cochrane Collaboration’s risk of bias tool for RCTs and the Risk of Bias in Non-randomized Studies (ROBINS-I) tool for non-randomized trials. Disagreements among reviewers were resolved by discussion and consensus within the committee.

Evidence synthesis
Data regarding baseline characteristics and core outcomes of each PICO question were extracted for analysis. The Mantel-Haenszel method or the inverse variance method with a random effects model was used to summarize treatment efficacy and safety. The meta-analysis was performed using RevMan software version 5.3 (Nordic Cochrane Centre, Copenhagen, Denmark) and Stata software version 13.1 (StataCorp LLC, College Station, TX, USA).

Grading the quality of evidence and strength of recommendations
The quality of evidence was rated for the important outcomes in each PICO question according to the GRADE approach. Briefly, the evidence supported by RCTs was considered to be high quality, while that of observational studies was considered to be low quality. Five factors were considered to possibly down-grade the study (risk of bias, inconsistency, indirectness, imprecision, and publication bias), and 3 factors were considered to possibly up-grade the study (large effects, dose response, and all plausible residual confounders). The classification of evidence quality is shown in Table 1.

The committee members determined the direction and strength of recommendations based on the following considerations: balance of benefits and undesirable consequences of intervention, quality of evidence, patient values and preferences, and feasibility. Briefly, 1 of the 2 grades (strong or conditional) was assigned to describe the strength of recommendations. We used the words “we recommend” for strong recommendations and “we suggest” for conditional recommendations. The criterion for a strong recommendation was evidence that the desirable effects clearly outweighed the undesirable effects (or vice versa). The criterion for a conditional recommendation was evidence that the desirable effects likely or slightly outweighed the undesirable effects. Table 2 shows the suggested interpretation of the strength of recommendations.

| Quality of evidence | Definition |
|---------------------|------------|
| High                | We are very confident that the true effect lies close to that of the estimate of the effect. |
| Moderate            | We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. |
| Low                 | Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. |
| Very low            | We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect. |
The recommendations were first generated by the committee and then sent for a public hearing, where an agreement on the criteria was more than 70% of votes in favor. If no agreement was reached, the PICO question was further discussed by the committee for possible adjustment of the recommendation.

**KEY QUESTIONS**

The following 13 clinical questions were addressed by the systematic literature review and evidence-to-decision frameworks according to the GRADE approach. All recommendations in Part 1 are summarized in Table 3 and Figure.

**Table 2. Interpretation of the strength of recommendations**

| Implications | Strong recommendation | Conditional recommendation |
|--------------|-----------------------|---------------------------|
| For patients | Most individuals in this situation would want the recommended course of action and only a small proportion would not. Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences. | The majority of individuals in this situation would want the suggested course of action, but many would not. |
| For clinicians | Most individuals should receive the intervention. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator. | Recognize that different choices will be appropriate for individual patients and that you must help each patient arrive at a management decision consistent with his or her values and preferences. Decision aids may be useful when helping individuals to make decisions consistent with their values and preferences. |
| For policy makers | The recommendation can be adapted as a policy or performance measure in most situations. | Policy making will require substantial debate and involvement of various stakeholders. Documentation of appropriate (e.g., shared) decision-making processes can serve as a performance measure. |

H1AH as the first-line therapy for CSU

| Regimen | Recommendation (evidence level) |
|---------|---------------------------------|
| • Non-sedating H1AH (than sedating H1AH) | • Strong (moderate) |
| • Up-dosing H1AHs up to 4-fold (if not improved with standard dose H1AH) | • Strong (low) |
| • Combination of H1AHs (if not improved with standard dose H1AH) | • Conditional (very low) |
| • Regular use of H1AHs (than as needed use) | • Conditional (very low) |

Add-on therapy (if not improved by H1AHs)

| Drugs | Recommendation (evidence level) |
|-------|---------------------------------|
| • Omalizumab | • Strong (moderate) |
| • Cyclosporine | • Conditional (low) |
| • H2AHs | • Conditional (low) |
| • LTRAs | • Conditional, against (low) |
| • Dapsone | • Conditional, against (low) |
| • Methotrexate | • Conditional, against (very low) |
| • Phototherapy | • Conditional (very low) |
| • Systemic corticosteroids | • Strong, against (very low) |

Figure. Treatment recommendations and evidence levels in the present guidelines for chronic spontaneous urticaria. Strong recommendations are highlighted in bold. Recommendations against the use are marked in italic and underlined.

CSU, chronic spontaneous urticaria; H1AHs, H1-antihistamines; H2AHs, H2-antihistamines; LTRA, leukotriene receptor antagonists.
I. **H<sub>1</sub>-antihistamines**

**Background**

Urticaria is a mast cell-driven disease. Histamine and other mediators released from activated mast cells lead to local sensory nerve activation, vasodilatation, extravasation,

| PICO                                                                 | Recommendation                                                                 |
|----------------------------------------------------------------------|--------------------------------------------------------------------------------|
| 1. Are non-sedating H<sub>1</sub>-antihistamines to be preferred over sedating H<sub>1</sub>-antihistamines as a first-line treatment of CSU? | We recommend non-sedating H<sub>1</sub>-antihistamines as a first-line treatment in adults and children with CSU (strong recommendation, moderate quality evidence). |
| 2. If there is no improvement following a standard dose of H<sub>1</sub>-antihistamines, should the dose of H<sub>1</sub>-antihistamines be increased? | We recommend up-dosing H<sub>1</sub>-antihistamines up to 4-fold in patients with CSU not responding to a standard dose of non-sedating H<sub>1</sub>-antihistamines (strong recommendation, low quality evidence). |
| 3. If there is no improvement following a standard dose of H<sub>1</sub>-antihistamines, should a combination of different H<sub>1</sub>-antihistamines be used? | We suggest a combination of different H<sub>1</sub>-antihistamines in patients with CSU not responding to a standard dose of non-sedating H<sub>1</sub>-antihistamines (conditional recommendation, very low-quality evidence). |
| 4. Should H<sub>1</sub>-antihistamines be taken regularly or as needed? | We suggest non-sedating H<sub>1</sub>-antihistamines be taken regularly by patients with CSU (conditional recommendation, very low-quality evidence). |

| Systemic corticosteroids                                               |                                                                              |
|----------------------------------------------------------------------|--------------------------------------------------------------------------------|
| 1. Are systemic corticosteroids useful as an add-on therapy in patients unresponsive to H<sub>1</sub>-antihistamines? | We do not recommend the routine use of systemic corticosteroids in patients not responding to H<sub>1</sub>-antihistamines (strong recommendation, very low-quality evidence). |

**II. H<sub>2</sub>-antihistamines**

1. Are H2-antihistamines useful as an add-on therapy in patients unresponsive to a standard dose of H<sub>1</sub>-antihistamines?

**III. Systemic corticosteroids**

1. Are systemic corticosteroids useful as an add-on therapy in patients unresponsive to H<sub>1</sub>-antihistamines?

**IV. Leukotriene receptor antagonists**

1. Are leukotriene receptor antagonists useful as an add-on therapy in patients unresponsive to a standard dose of H<sub>1</sub>-antihistamines?

**V. Omalizumab**

1. Is omalizumab useful in patients unresponsive to H<sub>1</sub>-antihistamines?

2. Is omalizumab useful as an add-on therapy in patients unresponsive to H<sub>1</sub>-antihistamines and other immunosuppressants?

**VI. Immunomodulators and others**

1. Is cyclosporin useful as an add-on therapy in patients unresponsive to high dose H<sub>1</sub>-antihistamines?

2. Is methotrexate useful as an add-on therapy in patients unresponsive to high dose H<sub>1</sub>-antihistamines?

3. Is dapsone useful as an add-on therapy in patients unresponsive to high dose H<sub>1</sub>-antihistamines?

4. Is phototherapy useful as an add-on therapy in patients unresponsive to high dose H<sub>1</sub>-antihistamines?
inflammatory cell recruitment. The main features of urticaria, including itching and wheals, are mediated by histamine, and therefore H\textsubscript{1}-antihistamines have been considered as the mainstay of treatment. Pharmacologically, they are inverse agonists with preferential affinity for inactive H\textsubscript{1}-histamine receptors, and H\textsubscript{1}-antihistamines stabilize the receptors in this inactive status.\textsuperscript{30} H\textsubscript{1}-antihistamines have been available since the 1950s, and first-generation H\textsubscript{1}-antihistamines have anticholinergic effects that may lead to undesirable side effects, such as rapid eye movement sleep disturbance, inattention, disorganized speech, or alterations in consciousness, which are more problematic in children and the elderly.\textsuperscript{31} Second-generation H\textsubscript{1}-antihistamines are largely free from anticholinergic side effects and are therefore generally considered in international guidelines to be the first choice for the management of CSU.\textsuperscript{32}

Generally, first generation H\textsubscript{1}-antihistamines is referred to as sedating H\textsubscript{1}-antihistamines and second generation H\textsubscript{1}-antihistamines as non-sedating H\textsubscript{1}-antihistamines. However, some uncertainty and controversy remain over the use of H\textsubscript{1}-antihistamines in the treatment of Korean patients with CSU, particularly in relation to drug selection, dose, and dosing intervals. According to a recent meta-analysis, the response rate to standard dose H\textsubscript{1}-antihistamines in patients with CSU is only approximately 40%.\textsuperscript{33} International practice guidelines\textsuperscript{32} recommend up-dosing non-sedating H\textsubscript{1}-antihistamines in patients who do not respond to a standard dose, and this is now also common practice in Korea. However, combining different H1-antihistamines is another common practice pattern in Korea and therefore the current guidelines include four major clinical questions regarding H\textsubscript{1}-antihistamines drug selection, dosage, and regimen, which were considered to be important by the guideline committee members.

**Question 1. Are non-sedating H\textsubscript{1}-antihistamines to be preferred over sedating H\textsubscript{1}-antihistamines as a first-line treatment of CSU?**

- Recommendation 1: We recommend non-sedating H\textsubscript{1}-antihistamines as a first-line treatment in adults and children with CSU (strong recommendation, moderate quality evidence).
- Summary of evidence: A total of 11 RCTs were identified.\textsuperscript{34-44} In meta-analyses of urticarial activity outcomes, the efficacy of non-sedating H\textsubscript{1}-antihistamines was slightly weaker, but not significantly different compared with sedating H\textsubscript{1}-antihistamines (risk ratio [RR], 1.06; 95% confidence interval [95% CI], 0.99–1.13). However, adverse drug reactions were significantly less frequent with non-sedating H\textsubscript{1}-antihistamines than with sedating H\textsubscript{1}-antihistamines (RR, 0.53; 95% CI, 0.39–0.73). Common adverse events in the sedating H1-antihistamines treatment groups were somnolence, lethargy, fatigue, headache, nausea, dizziness, and dry mouth.
- Remark: Based on evidence regarding the safety profile of sedating H\textsubscript{1}-antihistamines, the committee reached a consensus regarding a strong recommendation in favor of the use of non-sedating H\textsubscript{1}-antihistamines over sedating H\textsubscript{1}-antihistamines as the initial treatment of choice for patients with CSU. This view is in line with existing international guideline statements on the use of H\textsubscript{1}-antihistamines in different allergic conditions.\textsuperscript{31,32}

**Question 2. If there is no improvement after treatment with a standard dose of non-sedating H\textsubscript{1}-antihistamines, should the dose of H\textsubscript{1}-antihistamines be increased?**

- Recommendation 2: We recommend up-dosing non-sedating H\textsubscript{1}-antihistamines up to 4-fold in patients with CSU not responding to a standard dose of H\textsubscript{1}-antihistamines (strong recommendation, low quality evidence).
- Summary of evidence: Two RCTs,\textsuperscript{45,46} were identified as directly relevant to the PICO
question. In meta-analyses, 2-fold up-dosing of non-sedating H<sub>1</sub>-antihistamines was seen to be significantly more effective in improving pruritus symptom scores compared with standard dose maintenance (standard mean difference [SMD], −3.30; 95% CI, −4.71 to −1.90). In an open label study of 21 patients poorly responsive to cetirizine 10 mg daily for 1 or 2 weeks, cetirizine 20 mg daily significantly improved urticarial activity scores for wheal, itch, duration, and total scores, compared with the 10 mg daily regimen. In a double-blind, placebo-controlled cross-over trial of 20 patients refractory to conventional doses of second generation H<sub>1</sub>-antihistamines (fexofenadine 60 mg twice daily), treatment with 120 mg fexofenadine twice daily significantly decreased pruritus visual analogue scale (VAS) scores and the urticaria severity index at 4 weeks. None of these patients complained of fatigue or sleepiness in relation to the high dose treatment.

In meta-analyses of clinical trials without placebo control (such as sequential dose escalation) or in trials without a strict requirement for refractoriness to previous standard dose H<sub>1</sub>-antihistamines therapy in the patient selection criteria, the beneficial effects of high dose non-sedating H<sub>1</sub>-antihistamines (up to 2- or 4-fold) were also significant. The response rate to up-dosing in patients unresponsive to standard dose H<sub>1</sub>-antihistamines was approximately 60%.

Adverse effects increased with up-dosing of non-sedating H<sub>1</sub>-antihistamines, although the findings were not consistent. Drowsiness was found in 20% of patients receiving cetirizine 20 mg daily, which disappeared after decreasing the dosage to 10 mg daily. In a study involving 20 patients refractory to conventional doses of H<sub>1</sub>-antihistamines, none of the patients receiving 240 mg fexofenadine per day complained of fatigue or sleepiness. However, in a 4-week study comparing the efficacy and safety of different doses of rupatadine, somnolence was higher in the 20 mg rupatadine treatment group (21.43%) versus the lower intensity treatment groups (2.9% for placebo, 4.3% for 5 mg, and 5.4% for 10 mg rupatadine).

• Remark: In terms of efficacy, current evidence suggests up-dosing (up to 2- or 4-fold) is likely to be helpful in many patients not responsive to the standard dose regimen. Meta-analyses showed that the response rate to standard dose H<sub>1</sub>-antihistamines in patients with CSU is approximately 40%, whereas 60% of the unresponsive patients are likely to benefit from the up-dosing. However, adverse reactions (such as somnolence) increase in a dose-dependent manner, and 4-fold up-dosing may be problematic in vulnerable populations, such as children or the elderly. Therefore, in terms of the balance of risk-benefit, 2-fold up-dosing may be suggested over 4-fold up-dosing. In patients tolerant to high dose H<sub>1</sub>-antihistamines, a serial trial of 4-fold up-dosing may be considered. However, due to the relatively higher frequency of side effects, careful consideration of the risk-benefit balance is recommended when initiating 4-fold up-dosing therapy, particularly in children and the elderly.

**Question 3. If there is no improvement following a standard dose of non-sedating H<sub>1</sub>-antihistamines, should a combination of different H<sub>1</sub>-antihistamines be used?**

- **Recommendation 3:** We suggest a combination of different H<sub>1</sub>-antihistamines in patients with CSU not responding to a standard dose of non-sedating H<sub>1</sub>-antihistamines (conditional recommendation, very low-quality evidence).

- **Summary of evidence:** Only 1 study was identified. In a randomized study of 209 patients in China, a combination of mizolastine and ketotifen was superior to mizolastine alone in total efficacy rate (76.1% vs. 43.5%; P < 0.05) and recurrence rate (10.4% vs. 22.8%; P < 0.05) at 4 weeks. Adverse reactions were similar between the 2 treatment groups.

- **Remark:** There is very little evidence of the efficacy and safety of a combination of
different H1-antihistamines in patients not responding to a standard dose of a single H1-antihistamines. Given the additional benefits of H1-antihistamines up-dosing (up to 4-fold), similar therapeutic gains may be expected from a combination regimen. However, the safety of this approach will depend on the safety profiles and possible drug interactions of the combined drugs. Due to uncertainties regarding the efficacy and safety of different drug combinations, a combination regimen is less preferable than the up-dosing of a single H1-antihistamines. Therefore, the strength of this recommendation is considered conditional (i.e., weaker than that of up-dosing therapy).

Question 4. Should non-sedating H1-antihistamines be taken regularly or as needed by patients with CSU?

- Recommendation 4: We suggest that non-sedating H1-antihistamines be taken regularly by patients with CSU (conditional recommendation, very low-quality evidence).
- Summary of evidence: One RCT is directly relevant to this PICO question. A total of 106 patients responding to desloratadine 5 mg daily for 4 weeks were randomized to receive desloratadine daily (daily desloratadine plus placebo rescue tablet) or only on days when urticarial wheals were present (daily placebo plus desloratadine rescue tablet) for an additional 8 weeks. At 4 and 8 weeks after randomization, subjects taking daily desloratadine showed a statistically significant improvement in QoL scores compared with those taking desloratadine as needed.

One trial has evaluated the efficacy of on-demand H1-antihistamines to resolve existing wheals in patients with moderate-to-severe CSU. In this study, on-demand 5 mg desloratadine treatment significantly reduced the total hyperthermic skin area, but not wheal areas or volumes at 5 h compared with the group receiving no treatment.

- Remark: Despite very low quality of evidence, the committee members agreed that the evidence is in line with clinical experience. As urticarial attacks are frequent and unpredictable in patients with active CSU, a preventive strategy would be preferred over an on-demand approach.

II. H2-antihistamines

Background

H2-receptors are primarily involved in the process of gastric acid secretion, but they also account for approximately 15% of all histamine receptors in the skin. H2-antihistamines are associated with a relatively good safety profile and have been used empirically as an add-on therapy for patients with CSU who are not adequately controlled by H1-antihistamines; this approach was also recommended by some previous guidelines. However, in the recent 2018 EAACI/GA2LEN/EDF/WAO guidelines, the recommendation for H2-antihistamines use was removed due to a lack of supporting evidence. The purpose of this PICO question was to review the therapeutic benefits of H2-antihistamines in patients unresponsive to H1-antihistamines.

Question. Are H2-antihistamines useful as an add-on therapy in patients unresponsive to a standard dose of H1-antihistamines?

- Recommendation
  We suggest a trial of H2-antihistamines add-on therapy in patients not responding to a standard dose of H1-antihistamines (conditional recommendation, low quality evidence).
- Summary of evidence
  A total of 5 RCTs were identified. Four studies reported that cimetidine use in addition to H1-antihistamines (hydroxyzine, chlorpheniramine, or diphenhydramine) showed
significant benefits in terms of urticarial symptom scores compared with placebo. However, in an RCT of 32 patients with CSU, ranitidine as an add-on therapy to cetirizine failed to show any significant benefit over placebo in all measured efficacy outcomes, including urticarial activity score, chronic urticaria QoL questionnaire score, and patient-evaluated VAS scores. There were no significant differences in adverse events related to H$_2$-antihistamines add-on therapy.

**Remark**
A systematic review found very limited evidence mostly from a small number of older studies of cimetidine. The only recent study of ranitidine use failed to show any significant benefit over placebo as an add-on therapy to cetirizine, whereas the older studies of first-generation H$_1$-antihistamines plus cimetidine reported some benefit. Therefore, it is unclear whether H$_2$-antihistamines add-on may be beneficial in current management settings using newer generation H$_2$-antihistamines and H$_2$-antihistamines. However, H$_2$-antihistamines have a relatively good safety profile and degree of accessibility and, therefore, the committee agreed on a conditional recommendation for a trial of H$_2$-antihistamines add-on therapy in CSU patients not responding to standard dose H$_1$-antihistamines. However, it should be remembered that H$_2$-antihistamines add-on therapy is just one possible approach to add-on therapy, and it should be stopped if no improvement is seen within 1 or 2 months of the trial.

### III. Systemic corticosteroids

**Background**
Systemic corticosteroids are often considered when urticaria symptoms are severe or poorly controlled by standard therapies. However, repeated use can be harmful as it can cause serious complications, including diabetes mellitus, hypertension, osteoporosis, or fractures.

Therefore, current international guidelines suggest that it is reserved for use only in patients with an acute exacerbation of urticaria.

**Question. Are systemic corticosteroids useful as an add-on therapy in patients unresponsive to H$_1$-antihistamines?**
- **Recommendation:** We do not recommend a routine use of systemic corticosteroids in patients not responding to H$_1$-antihistamines (strong recommendation, very low quality evidence). A short-term use (within 10 days) may only be considered in limited circumstances, especially for relieving severe symptoms in patients with acute aggravation of CSU.
- **Summary of evidence:** Only 3 retrospective observational studies were identified. In one retrospective study of 750 patients with H$_1$-antihistamine-refractory CSU, short-term (10 days) systemic corticosteroid treatment was helpful in controlling transient aggravation, and approximately 50% of the study population benefitted from a single dose of systemic corticosteroids; however, approximately 15% of patients still did not respond to systemic corticosteroids. In a study of 641 Korean patients with CSU, the influence of initial treatment on the long-term control of urticaria was evaluated; in this study, the time to reach a controlled state did not differ between those who received H$_1$-antihistamines monotherapy vs. those treated with a combination of oral corticosteroids. In a Japanese study of 386 patients with either acute or CSU, the use of systemic corticosteroids was not significantly associated with the remission of urticaria.
- **Remark:** There is no good quality evidence (such as RCTs) to determine the efficacy of systemic corticosteroids in patients with refractory urticaria. However, observational
studies suggest that while corticosteroids may be useful in relieving acute symptoms, this approach may not be helpful in modifying the long-term course of disease. Given the substantial side effects associated with chronic systemic corticosteroid exposure such as osteoporosis, fracture or diabetes mellitus, short-term use (within 10 days) only may be considered for acute symptom relief in patients with CSU flare-up.

CONCLUSIONS

CSU is a common condition associated with substantial disease burden. It frequently persists for several years and requires high-intensity treatment. Patients may experience deterioration in QoL and medication-associated complications. During the last decade, there have been major advances in the pharmacological treatment of CSU. There is an outstanding need for clinical practice guidelines that reflect local circumstances and practice patterns in Korea, and this work is the first joint initiative of the KAAACI and the KDA to provide evidence-based guidance for the management of CSU in Korean adults and children. In Part I of the present guidelines, disease definition, guideline scope, and development methodology as well as recommendations on the use of antihistamines and corticosteroids were summarized. There is a strong consensus that non-sedating H₁-antihistamines are the first-line drug for patients with CSU, supported by quality evidence for its efficacy and safety profile. In patients not responding to a standard dose of H₁-antihistamines, up-dosing regimens are strongly recommended (up to 4-fold), but also a combination of different H₁-antihistamines or an addition of H₂-antihistamines may be considered. The routine use of systemic corticosteroids should be avoided due to substantial adverse effects, such as osteoporosis, fracture or diabetes mellitus; a short-term use (within 10 days) may only be considered in limited circumstances, especially for relieving severe symptoms in patients with acute aggravation of CSU. In Part 2 of this guideline, treatment options for patients with antihistamine-refractory CU are addressed.

ACKNOWLEDGMENTS

This guideline for chronic urticaria was developed with the support of the Korean Academy of Asthma, Allergy and Clinical Immunology and the Korean Dermatological Association.

REFERENCES

1. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011;66:317-30. [PUBMED] [CROSSREF]
2. Antia C, Baquerizo K, Korman A, Bernstein JA, Alikhan A. Urticaria: a comprehensive review: epidemiology, diagnosis, and work-up. J Am Acad Dermatol 2018;79:599-614. [PUBMED] [CROSSREF]
3. Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol 2010;35:869-73. [PUBMED] [CROSSREF]
4. Chu CY, Cho YT, Jiang IH, Lin EI, Tang CH. Epidemiology and comorbidities of patients with chronic urticaria in Taiwan: a nationwide population-based study. J Dermatol Sci 2017;88:192-8. [PUBMED] [CROSSREF]
5. Kim YS, Park SH, Han K, Bang CH, Lee JH, Park YM. Prevalence and incidence of chronic spontaneous urticaria in the entire Korean adult population. Br J Dermatol 2018;178:976-7. [PUBMED] [CROSSREF]

6. Kim BR, Yang S, Choi JW, Choi CW, Youn SW. Epidemiology and comorbidities of patients with chronic urticaria in Korea: a nationwide population-based study. J Dermatol 2018;45:10-6. [PUBMED] [CROSSREF]

7. Lee N, Lee JD, Lee HY, Kang DR, Ye YM. Epidemiology of chronic urticaria in Korea using the Korean Health Insurance Database, 2010–2014. Allergy Asthma Immunol Res 2017;9:438-45. [PUBMED] [CROSSREF]

8. Lee SJ, Ha EK, Lee HM, Lee KS, Lee SW, Kim MA, et al. Prevalence and risk factors of urticaria with a focus on chronic urticaria in children. Allergy Asthma Immunol Res 2017;9:212-9. [PUBMED] [CROSSREF]

9. Shin M, Lee S. Prevalence and causes of childhood urticaria. Allergy Asthma Immunol Res 2017;9:189-90. [PUBMED] [CROSSREF]

10. Eun SJ, Lee JY, Kim DY, Yoon HS. Natural course of new-onset urticaria: Results of a 10-year follow-up, nationwide, population-based study. Allergol Int 2019;68:52-8. [PUBMED] [CROSSREF]

11. Kim YS, Park SH, Han K, Lee JH, Kim NL, Roh JY, et al. Clinical course of chronic spontaneous urticaria in the Korean adult population. Allergy Asthma Immunol Res 2018;10:83-7. [PUBMED] [CROSSREF]

12. Park H, Lee JY, Song A, Jung M, Kim M, Sohn I, et al. Natural course and prognostic factors of chronic urticaria in Korean children: a single center experience. Asian Pac J Allergy Immunol 2019;37:19-24. [PUBMED] [CROSSREF]

13. Kim YS, Han K, Lee JH, Kim NL, Roh JY, Seo SJ, et al. Increased risk of chronic spontaneous urticaria in patients with autoimmune thyroid diseases: a nationwide, population-based study. Allergy Asthma Immunol Res 2017;9:373-7. [PUBMED] [CROSSREF]

14. Kim YS, Han K, Lee JH, Lee JY, Park YM. Can Body mass index and/or waist circumference be the risk factors of chronic spontaneous urticaria?: a nationwide population-based study. Ann Dermatol 2019;31:482-5. [CROSSREF]

15. Vietri J, Turner SJ, Tian H, Isherwood G, Balp MM, Gabriel S. Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. Ann Allergy Asthma Immunol 2015;115:306-11. [PUBMED] [CROSSREF]

16. Ye YM, Park JW, Kim SH, Choi JH, Hur GY, Lee HY, et al. Clinical evaluation of the computerized chronic urticaria-specific quality of life questionnaire in Korean patients with chronic urticaria. Clin Exp Dermatol 2012;37:722-8. [PUBMED] [CROSSREF]

17. Hoskin B, Ortiz B, Paknis B, Kavati A. Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use. Curr Med Res Opin 2019;35:1387-95. [PUBMED] [CROSSREF]

18. Kang MJ, Kim HS, Kim HO, Park YM. The impact of chronic idiopathic urticaria on quality of life in Korean patients. Ann Dermatol 2009;21:226-9. [PUBMED] [CROSSREF]

19. Lee EA, Kim HS, Lee JY, Kim HO, Park YM. Analysis of the effect of oral antihistamines in patients with chronic urticaria in terms of the disease outcome and quality of life. Korean J Dermatol 2010;48:758-65. [PUBMED] [CROSSREF]

20. Lee JH, Bae YI, Lee SH, Kim SC, Lee HY, Ban GY, et al. Adaptation and validation of the Korean version of the urticaria control test and its correlation with salivary cortisone. Allergy Asthma Immunol Res 2019;11:55-67. [PUBMED] [CROSSREF]

21. Choi WS, Lim ES, Ban GY, Kim JH, Shin YS, Park HS, et al. Disease-specific impairment of the quality of life in adult patients with chronic spontaneous urticaria. Korean J Intern Med 2018;33:185-92. [PUBMED] [CROSSREF]

22. Kim YS, Bang CH, Lee JH, Lee JY, Park YM. Self-reported provoking physical factors in patients with chronic urticaria: a questionnaire study. Ann Dermatol 2018;30:478-80. [PUBMED] [CROSSREF]

23. Uguz F, Engin B, Yilmaz E. Axis I and axis II diagnoses in patients with chronic idiopathic urticaria. J Psychosom Res 2008;64:225-9. [PUBMED] [CROSSREF]
24. Kulthanan K, Chusakul S, Recto MT, Gabriel MT, Aw DC, Prepageran N, et al. Economic burden of the inadequate management of allergic rhinitis and urticaria in Asian countries based on the GA2LEN model. Allergy Asthma Immunol Res 2018;10:370-8.

25. Guillet G, Bécherel PA, Pralong P, Delbarre M, Outtas O, Martin L, et al. The burden of chronic urticaria: French baseline data from the international real-life AWARE study. Eur J Dermatol 2019;29:49-54.

26. Guyatt G, Oxman AD, Akl EA, Kunz R, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.

27. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.

28. Kaplan AP. Chronic spontaneous urticaria: pathogenesis and treatment considerations. Allergy Asthma Immunol Res 2017;9:477-82.

29. Min TK, Saini SS. Emerging therapies in chronic spontaneous urticaria. Allergy Asthma Immunol Res 2019;11:470-81.

30. Leurs R, Church MK, Taglialetela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-98.

31. Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy 2010;65:459-66.

32. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Webner B, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73:1393-414.

33. Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, Guillén-Grima F, Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol 2016;175:1153-65.

34. Boggs PB, Ellis CN, Grossman J, Washburne WF, Gupta AK, Ball R, et al. Double-blind, placebo-controlled study of terfenadine and hydroxyzine in patients with chronic idiopathic urticaria. Ann Allergy 1989;63:616-20.

35. Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996;30:1075-9.

36. Fredriksson T, Hersle K, Hjorth N, Moberken H, Persson T, Salde L, et al. Terfenadine in chronic urticaria: a comparison with clemastine and placebo. Cutis 1986;38:128-30.

37. Ishibashi Y, Harada S, Kukita A, Nishikawa T, Yoshida H, Okawara A, et al. A clinical study of astemizole (MJD-30) in treating chronic urticaria: a double blind, comparative study using ketotifen fumarate as a control drug. Rinsho Iyaku 1990;6:1623-38.

38. Ishibashi Y, Harada S, Niimura M, Ueda H, Imamura S, Yamamoto S, et al. Clinical evaluation of KG-2413 (emendastine difumarate) on chronic urticaria by multicenter double-blind study: comparative Study between 2 mg/day, 4 mg/day, and ketotifen fumarate. Rinsho Iyaku 1990;6:141-59.

39. Kukita A, Harada S, Okawara A, Takahashi M, Tagami H, Ishikawa H, et al. Phase III study of WAL801C1L (Epinastine) on chronic urticaria: a double blind study in comparison with ketotifen fumarate. Rinsho Iyaku 1991;7:2303-20.

40. Kukita A, Harada S, Yoshida H, Ishibashi Y, Niimura M, Yamamoto S, et al. Phase III study of LAS-90 on chronic urticaria: double blind comparative study with ketotifen fumarate. Rinsho Iyaku 1994;10:895-912.

41. Sussman G, Jancelewicz Z. Controlled trial of H1 antagonists in the treatment of chronic idiopathic urticaria. Ann Allergy 1991;67:433-9.
42. Grant JA, Bernstein DI, Buckley CE, Chu T, Fox RW, Rocklin RE, et al. Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1988;81:574-9.

43. Kalivas J, Breneman D, Tharp M, Bruce S, Bigby M; nine other investigators. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol 1990;86:1014-8.

44. La Rosa M, Leonardi S, Marchese G, Corrias A, Barberio G, Oggiuno N, et al. Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. Ann Allergy Asthma Immunol 2001;87:48-53.

45. Kameyoshi Y, Tanaka T, Miha S, Takahagi S, Niimi N, Hide M. Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients. Br J Dermatol 2007;157:803-4.

46. Tanizaki H, Nakahigashi K, Miyachi Y, Kabashima K. Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. J Dermatolog Treat 2013;24:477-80.

47. Dubertret L, Zaluca L, Cristodouro L, Benea V, Medina I, Fantin S, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007;17:223-8.

48. Wang HJ, Zhang JA, Yu JB. Clinical observation of long-term decrement mizolastine therapy in the treatment of chronic urticaria. J Clin Dermatol 2012;41:440-2.

49. Grob JJ, Auquier P, Dreyfus I, Ortonne JP. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2009;64:605-12.

50. Weller K, Ardelcian E, Schol E, Martus P, Zuberbier T, Maurer M. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol 2013;93:168-74.

51. Lippert U, Artuc M, Guaitzka A, Babina M, Guhl S, Haase I, et al. Human skin mast cells express H2 and H4, but not H3 receptors. J Invest Dermatol 2004;123:116-23.

52. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014;133:1270-7.

53. Sánchez-Borges M, Asero R, Ansotegui IJ, Baiardini I, Bernstein JA, Canonica GW, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J 2012;5:125-47.

54. Zuberbier T, Bernstein JA. A comparison of the United States and international perspective on chronic urticaria guidelines. J Allergy Clin Immunol Pract 2018;6:1144-51.

55. Harvey RP, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol 1981;68:262-6.

56. Bleehen SS, Thomas SE, Greaves MW, Newton J, Kennedy CT, Hindley F, et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol 1987;117:81-8.

57. Guevara-Gutierrez E, Bonilla-Lopez S, Hernández-Arana S, Tlacuilo-Parra A. Safety and efficacy of cetirizine versus cetirizine plus ranitidine in chronic urticaria: double-blind randomized placebo-controlled study. J Dermatolog Treat 2015;26:548-50.

58. Monroe EW, Cohen SH, Kalbfleisch J, Schulz CI. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol 1981;117:404-7.

59. Commens CA, Greaves MW. Cimetidine in chronic idiopathic urticaria: a randomized double-blind study. Br J Dermatol 1978;99:675-9.
60. Antia C, Baquerizo K, Korman A, Alikhan A, Bernstein JA. Urticaria: a comprehensive review: treatment of chronic urticaria, special populations, and disease outcomes. J Am Acad Dermatol 2018;79:617-33.

61. Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol 2010;20:386-90.

62. Kim S, Back S, Shin B, Yoon SY, Park SY, Lee T, et al. Influence of initial treatment modality on long-term control of chronic idiopathic urticaria. PLoS One 2013;8:e69345.

63. Tanaka T, Hiragun M, Hide M, Hiragun T. Analysis of primary treatment and prognosis of spontaneous urticaria. Allergol Int 2017;66:458-62.

64. Ye YM, Park JW, Kim SH, Ban GY, Kim JH, Shin YS, et al. Prognostic factors for chronic spontaneous urticaria: a 6-month prospective observational study. Allergy Asthma Immunol Res 2016;8:115-23.